# Structure Therapeutics Inc.: overview

GPCR · Nasdaq · CIK 1888886 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gpcr.md) · [Financials](/companies/gpcr/financials.md) · [Filings](/companies/gpcr/filings.md) · [Insiders](/companies/gpcr/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.20)](/filings/0001104659-25-107829.md) | not reported | [(0.27)](/filings/0001104659-26-057230.md) | [(0.36)](/filings/0001104659-26-092057.md) | [(0.37)](/filings/0001104659-25-107829.md) | not reported | [(0.35)](/filings/0001104659-26-057230.md) | [(0.49)](/filings/0001104659-26-092057.md) |
| Free cash flow | $m | [(20.4) d](/filings/0001104659-25-107829.md) | [(36.5) d](/filings/0001104659-26-020562.md) | [(52.5)](/filings/0001104659-26-057230.md) | [(54.8) d](/filings/0001104659-26-092057.md) | [(52.6) d](/filings/0001104659-25-107829.md) | [(65.9) d](/filings/0001104659-26-020562.md) | [14.1](/filings/0001104659-26-057230.md) | [(120) d](/filings/0001104659-26-092057.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(5.51)](/filings/0001558370-24-002791.md) | [(0.81)](/filings/0001104659-26-020562.md) | [(0.78)](/filings/0001104659-26-020562.md) | [(0.80)](/filings/0001104659-26-020562.md) |
| Free cash flow | $m | [(46.3)](/filings/0001558370-24-002791.md) | [(81.7)](/filings/0001104659-26-020562.md) | [(118)](/filings/0001104659-26-020562.md) | [(226)](/filings/0001104659-26-020562.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gpcr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $419.2m | 7,810,306 |  | Reduced −593,143 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $396.1m | 7,379,433 |  | Added +119,146 |
| [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $351.8m | 6,555,555 |  | Unchanged |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $279.3m | 5,204,212 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $258.3m | 5,354,981 |  | Not compared |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $254.4m | 4,740,072 |  | Added +460,224 |
| [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $180.7m | 3,366,823 |  | Reduced −92,535 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $150.6m | 2,806,640 |  | Added +501,183 |
| [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $118.6m | 2,209,400 |  | Added +733,997 |
| [PRINCIPAL FINANCIAL GROUP INC](/funds/1126328.md) | 2026-06-30 | $94.1m | 1,752,753 |  | Reduced −1,011 |

## Recent filings

[All 270 filings](/companies/gpcr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-08 | 08:09 ET | [8-K](/filings/0001104659-26-105688.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-105688 |
| 2026-08-06 | 16:29 ET | [10-Q](/filings/0001104659-26-092057.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092057 |
| 2026-08-06 | 16:13 ET | [8-K](/filings/0001104659-26-092017.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-092017 |
| 2026-06-18 | 16:05 ET | [8-K](/filings/0001104659-26-075720.md) | 5.07 Shareholder vote results | 0001104659-26-075720 |
| 2026-05-07 | 16:45 ET | [10-Q](/filings/0001104659-26-057230.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057230 |
| 2026-05-07 | 16:42 ET | [8-K](/filings/0001104659-26-057226.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-057226 |
| 2026-04-23 | 16:30 ET | [DEF 14A](/filings/0001104659-26-047740.md) | Proxy statement, period 2026-06-17 | 0001104659-26-047740 |
| 2026-04-15 | 06:05 ET | [8-K](/filings/0001104659-26-043425.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-043425 |
| 2026-03-16 | 08:01 ET | [8-K](/filings/0001104659-26-028023.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-028023 |
| 2026-02-26 | 16:40 ET | [10-K](/filings/0001104659-26-020562.md) | Annual report, period 2025-12-31 | 0001104659-26-020562 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-020562.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1888886
- Tickers: GPCR
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: E9
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.